Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy

Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy

Arash A Horizon1, Robert J Joseph2, Qiming Liao3, Steven T Ross3, Gary E Pakes31Center for Rheumatology, 2Surgical Podiatry, Los Angeles, CA, USA; 3GlaxoSmithKline, Research Triangle Park, NC, USASummary: In a retrospective case series study, medical records were evaluated for all male patients infe...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Horizon AA, Joseph RJ, Liao Q, Ross ST, Pakes GE
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2011
Materias:
Immunologic diseases. Allergy
RC581-607
Acceso en línea:https://doaj.org/article/7752c3bad44b425bbec0476c38d10408
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:7752c3bad44b425bbec0476c38d10408
record_format dspace
spelling oai:doaj.org-article:7752c3bad44b425bbec0476c38d104082021-12-02T00:14:08ZCharacteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy1179-1373https://doaj.org/article/7752c3bad44b425bbec0476c38d104082011-06-01T00:00:00Zhttp://www.dovepress.com/characteristics-of-foot-fractures-in-hiv-infected-patients-previously--a7751https://doaj.org/toc/1179-1373Arash A Horizon1, Robert J Joseph2, Qiming Liao3, Steven T Ross3, Gary E Pakes31Center for Rheumatology, 2Surgical Podiatry, Los Angeles, CA, USA; 3GlaxoSmithKline, Research Triangle Park, NC, USASummary: In a retrospective case series study, medical records were evaluated for all male patients infected with human immunodeficiency virus (HIV) diagnosed over a one-year period with foot fractures (n = 30) confirmed by magnetic resonance imaging at a Los Angeles outpatient private practice rheumatology clinic. Proportionally more patients had received tenofovir prefracture (17 [57%]) than those who had not (13 [43%]). At fracture diagnosis, these two groups were similar in median age (49 versus 48 years), HIV-1 RNA (both 1.7 log10 copies/mL), CD4 count (300 versus 364/mm3), time between HIV diagnosis and foot fracture (both 17 years), family history of degenerative bone disease (24% versus 23%), prevalence of malabsorption syndrome, renal failure, calcium deficiency, or vitamin D deficiency, and concurrent use of bisphosphonates, calcitonin, and diuretics. However, more tenofovir-treated patients had osteoporosis (35% versus 8%), stress-type fractures (53% versus 31%), concurrent fractures (12% versus 0%), wasting syndrome (29% versus 15%), truncal obesity (18% versus 8%), smoked cigarettes (more than one pack/day for more than one year; 35% versus 8%), dual energy X-ray absorptiometry (DEXA) T scores <–2.4 (denoting osteoporosis) at the femur (24% versus 9%) and spine (47% versus 36%), and had received protease inhibitors (71% versus 46%), non-nucleoside reverse transcriptase inhibitors (24% versus 0%), prednisone (24% versus 0%), testosterone (47% versus 23%), and teriparatide (29% versus 8%). Median time from tenofovir initiation until fracture was 2.57 (range 1.17–5.69) years. In conclusion, more foot fractures were observed in tenofovir-treated patients than in non-tenofovir-treated patients with HIV infection. Comorbidities and/or coadministered drugs may have been contributory.Keywords: HIV infection, fractures, antiretroviral therapy, tenofovirHorizon AAJoseph RJLiao QRoss STPakes GEDove Medical PressarticleImmunologic diseases. AllergyRC581-607ENHIV/AIDS: Research and Palliative Care, Vol 2011, Iss default, Pp 53-59 (2011)
institution DOAJ
collection DOAJ
language EN
topic Immunologic diseases. Allergy
RC581-607
spellingShingle Immunologic diseases. Allergy
RC581-607
Horizon AA
Joseph RJ
Liao Q
Ross ST
Pakes GE
Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy
description Arash A Horizon1, Robert J Joseph2, Qiming Liao3, Steven T Ross3, Gary E Pakes31Center for Rheumatology, 2Surgical Podiatry, Los Angeles, CA, USA; 3GlaxoSmithKline, Research Triangle Park, NC, USASummary: In a retrospective case series study, medical records were evaluated for all male patients infected with human immunodeficiency virus (HIV) diagnosed over a one-year period with foot fractures (n = 30) confirmed by magnetic resonance imaging at a Los Angeles outpatient private practice rheumatology clinic. Proportionally more patients had received tenofovir prefracture (17 [57%]) than those who had not (13 [43%]). At fracture diagnosis, these two groups were similar in median age (49 versus 48 years), HIV-1 RNA (both 1.7 log10 copies/mL), CD4 count (300 versus 364/mm3), time between HIV diagnosis and foot fracture (both 17 years), family history of degenerative bone disease (24% versus 23%), prevalence of malabsorption syndrome, renal failure, calcium deficiency, or vitamin D deficiency, and concurrent use of bisphosphonates, calcitonin, and diuretics. However, more tenofovir-treated patients had osteoporosis (35% versus 8%), stress-type fractures (53% versus 31%), concurrent fractures (12% versus 0%), wasting syndrome (29% versus 15%), truncal obesity (18% versus 8%), smoked cigarettes (more than one pack/day for more than one year; 35% versus 8%), dual energy X-ray absorptiometry (DEXA) T scores <–2.4 (denoting osteoporosis) at the femur (24% versus 9%) and spine (47% versus 36%), and had received protease inhibitors (71% versus 46%), non-nucleoside reverse transcriptase inhibitors (24% versus 0%), prednisone (24% versus 0%), testosterone (47% versus 23%), and teriparatide (29% versus 8%). Median time from tenofovir initiation until fracture was 2.57 (range 1.17–5.69) years. In conclusion, more foot fractures were observed in tenofovir-treated patients than in non-tenofovir-treated patients with HIV infection. Comorbidities and/or coadministered drugs may have been contributory.Keywords: HIV infection, fractures, antiretroviral therapy, tenofovir
format article
author Horizon AA
Joseph RJ
Liao Q
Ross ST
Pakes GE
author_facet Horizon AA
Joseph RJ
Liao Q
Ross ST
Pakes GE
author_sort Horizon AA
title Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy
title_short Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy
title_full Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy
title_fullStr Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy
title_full_unstemmed Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy
title_sort characteristics of foot fractures in hiv-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy
publisher Dove Medical Press
publishDate 2011
url https://doaj.org/article/7752c3bad44b425bbec0476c38d10408
work_keys_str_mv AT horizonaa characteristicsoffootfracturesinhivinfectedpatientspreviouslytreatedwithtenofovirversusnontenofovircontaininghighlyactiveantiretroviraltherapy
AT josephrj characteristicsoffootfracturesinhivinfectedpatientspreviouslytreatedwithtenofovirversusnontenofovircontaininghighlyactiveantiretroviraltherapy
AT liaoq characteristicsoffootfracturesinhivinfectedpatientspreviouslytreatedwithtenofovirversusnontenofovircontaininghighlyactiveantiretroviraltherapy
AT rossst characteristicsoffootfracturesinhivinfectedpatientspreviouslytreatedwithtenofovirversusnontenofovircontaininghighlyactiveantiretroviraltherapy
AT pakesge characteristicsoffootfracturesinhivinfectedpatientspreviouslytreatedwithtenofovirversusnontenofovircontaininghighlyactiveantiretroviraltherapy
_version_ 1718403872061390848

Ejemplares similares